Table 4.

Potential Obesogenic Actions of EDCs

  • Agonist at PPARᵧ and RXRα (32)
  • Promotion of adipogenesis through ERs (33)
  • Increase in enzymatic activity of 11-β hydroxysteroid dehydrogenase type 1 (11-β HSD type 1) (34)
  • Increase in insulin stimulated lipogenesis (35)
  • Alterations in blood levels of insulin, leptin, and adiponectin (36)
  • Alteration of central energy regulatory pathways (37)
  • Decreased TRH expression and type 4 melanocortin receptors in the paraventricular nucleus of the hypothalamus and stimulation of orexigenic pathways (38)
  • Epigenetic transgenerational inheritance of adult-onset obesity (39)

From: Endocrine Disruptor Chemicals

Cover of Endotext
Endotext [Internet].
Feingold KR, Anawalt B, Blackman MR, et al., editors.
South Dartmouth (MA): MDText.com, Inc.; 2000-.
Copyright © 2000-2024, MDText.com, Inc.

This electronic version has been made freely available under a Creative Commons (CC-BY-NC-ND) license. A copy of the license can be viewed at http://creativecommons.org/licenses/by-nc-nd/2.0/.

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.